CCL4‐mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease

Inflammatory bowel disease (IBD) has emerged a global disease and the ascending incidence and prevalence is accompanied by elevated morbidity, mortality, and substantial healthcare system costs. However, the current typical one‐size‐fits‐all therapeutic approach is suboptimal for a substantial propo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Wenbin, Yu, Jiafei, Zheng, Tao, Liu, Peizhao, Zhao, Fan, Liu, Juanhan, Hong, Zhiwu, Ren, Huajian, Gu, Guosheng, Wang, Gefei, Wu, Xiuwen, Zhao, Yun, Ren, Jianan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888545/
https://www.ncbi.nlm.nih.gov/pubmed/33634985
http://dx.doi.org/10.1002/ctm2.339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888545/
https://www.ncbi.nlm.nih.gov/pubmed/33634985
http://dx.doi.org/10.1002/ctm2.339

Ejemplares similares